Life sciences tools clinical research reported revenue growth contribution measures how much disclosed clinical research growth contributes to reported growth in Thermo Fisher Scientific's Laboratory Products and Biopharma Services segment.
Thermo Fisher said clinical research revenue increased $441M in the second quarter of 2026 and contributed 7 percentage points of reported segment growth.
Clario was the primary driver of reported growth
Thermo Fisher said the increase was primarily driven by the March 2026 Clario acquisition.
That acquisition effect matters because reported segment revenue grew 12%, while organic revenue growth was 5%.
Reported contribution is not organic demand growth
The contribution isolates a disclosed business-level driver of reported sales, but it does not remove acquisition or currency effects.
Compare it with Laboratory Products and Biopharma Services organic revenue growth and segment income margin.
Primary source: Thermo Fisher Scientific Q2 2026 Form 10-Q.
Part of the Life Sciences Tools & Biopharma Services Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- TMOOpen operating-model research →10 of 10 reviewed concepts in Life Sciences Tools & Biopharma Services EconomicsReported business-growth contribution2 of 2 bridge concepts supportedContinue through this bridge:Bioproduction Growth Contribution
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare clinical research growth contributions
Compare disclosed clinical-research contributions to reported segment growth with acquisition effects explicitly retained.
Explore more topics in the Financial Research Encyclopedia.